Business, energy, technology, markets and global industry news from Business News Today

Servier Pharmaceuticals

PharmaDeviceNews Servier Pharmaceuticals
Representative image of a pediatric oncology consultation as Servier and Day One advance FIREFLY-2, a pivotal trial testing OJEMDA as a potential front-line treatment for BRAF-altered pediatric low-grade glioma.
Pharma & Biotech

Servier has nine glioma abstracts for SNO 2026, but can the data expand its treatment reach?

Servier reveals its SNO 2026 plans for Voranigo and Ojemda, with long-term glioma outcomes, treatment durability and potential expansion in focus.

Read More
Representative image of a pediatric oncology consultation as Servier and Day One advance FIREFLY-2, a pivotal trial testing OJEMDA as a potential front-line treatment for BRAF-altered pediatric low-grade glioma.
Pharma & Biotech

Why Servier’s FIREFLY-2 enrollment milestone could reshape pediatric glioma treatment

OJEMDA is already approved after relapse. FIREFLY-2 asks whether Servier can move targeted pLGG therapy earlier.

Read More